2-Methyl-2-Propanyl (3R)-3-Amino-1-Pyrrolidinecarboxylate Hydrochloride (1:1)

Chiral Phosphoric Acid Ligand Synthesis and the Role of Tert-Butyl Carbamate Protection

The hydrochloride provides a bench-stable, pre-weighed source of the (3R)-aminopyrrolidine base, which is liberated in situ prior to phosphorylation. In a standard procedure conducted under anhydrous argon, 1.0 eq of 2-Methyl-2-propanyl (3R)-3-amino-1-pyrrolidinecarboxylate hydrochloride is suspended in dichloromethane (10 volumes relative to substrate) and neutralized with triethylamine (2.5 eq) at 0°C to prevent exothermic decomposition of the intermediate free amine. The resulting free base solution is filtered through a short plug of neutral alumina to remove triethylammonium chloride, then added dropwise over 45 minutes to a pre-cooled (−10°C to −5°C) solution of (R)-3,3′-diphenyl-1,1′-binaphthyl-2,2′-diyl chlorophosphate (1.05 eq) in THF. Maintaining the internal temperature below 0°C during the addition suppresses nucleophilic displacement at the binaphthol oxygen atoms, a side reaction that depresses the yield of the desired phosphoramidate by up to 12% when the temperature exceeds +5°C. After stirring for 16 h at ambient temperature, the Boc-protected intermediate is isolated by column chromatography (silica gel, gradient from ethyl acetate/hexane 1:4 to 1:1) and treated with HCl/dioxane (4M, 6 eq of HCl) at 20°C for 2 h. The deprotection must be monitored by ³¹P NMR because overexposure to strong acid can cleave the phosphorus–nitrogen bond, generating 3-aminopyrrolidine and the parent phosphoric acid. The final chiral phosphoric acid, obtained as a zwitterionic solid after trituration with methyl tert-butyl ether, is characterized by specific rotation measured at 589 nm in methanol (c = 1.0) and chiral HPLC purity using a Chiralpak IC column (eluent: n-hexane/2-propanol/trifluoroacetic acid 70:30:0.1) per modified USP 〈621〉 conditions. This catalyst is subsequently employed in enantioselective transfer hydrogenation of benzoxazine-acetals, a step critical to the commercial route toward HCV NS5B polymerase inhibitors. Process-scale batches manufactured under ICH Q7 guidelines for active pharmaceutical ingredient starting materials require control of residual palladium (≤ 10 ppm, by inductively coupled plasma mass spectrometry per USP 〈232〉) and residual triethylamine (≤ 500 ppm, headspace GC per USP 〈467〉), as these impurities poison the downstream asymmetric hydrogenation catalyst.

In the construction of heterobifunctional protein degraders, the (3R)-configuration of the pyrrolidine ring imparts a defined kink angle that situates the E3 ligase ligand favorably for ternary complex formation with the protein of interest. The hydrochloride is transformed into a Boc-protected amino-pyrrolidine acetic acid linker module through alkylation with tert-butyl bromoacetate. A representative batch record for the alkylation step charges 1.0 eq of the substrate hydrochloride in acetonitrile (8 volumes) with powdered potassium carbonate (3.0 eq) and a catalytic quantity of tetrabutylammonium iodide (0.05 eq). The mixture is heated to 60°C for 20 h; conversion below 95% at this point indicates moisture ingress and requires azeotropic drying with toluene before re-charging the alkylating agent. After filtration and solvent displacement into ethyl acetate, the protected amino ester is isolated by vacuum distillation (bp 108–112°C at 0.3 mbar) on a wiped-film evaporator to avoid thermal deprotection of the Boc group. The subsequent amide coupling with a von Hippel–Lindau (VHL) ligand carboxylic acid—commonly performed with HATU (1.15 eq) and N,N-diisopropylethylamine (3.0 eq) in DMF at 0°C warming to 23°C over 4 h—delivers the protected linker–ligand conjugate. Deprotection with trifluoroacetic acid/triisopropylsilane/water (95:2.5:2.5 v/v/v) at 20°C for 1 h and precipitation from cold diethyl ether affords the VHL-recruiting PROTAC linker intermediate as its trifluoroacetate salt. This intermediate is coupled to a target protein ligand, for instance a BET bromodomain inhibitor or an androgen receptor antagonist, yielding a degrader molecule where the (3R)-pyrrolidine spacer contributes to a measured degradation stoichiometry approaching 1:1 as quantified by global proteomics. Quality control for material destined for Phase I clinical supply follows ICH M7 guidelines for mutagenic impurities: the tertiary amine alkylation step requires monitoring of the bromoacetate ester alkylating agent by GC-MS (limit of detection 1 µg/g) and confirmation of enantiomeric excess by chiral supercritical fluid chromatography (SFC) on a Chiralpak AD-H column under isocratic conditions (CO₂/methanol 80:20, 40°C, 100 bar backpressure) to a specification of ≥ 99.0% ee.

What Reaction Parameters Drive Enantiomeric Excess Above 99.5% in Factor Xa Inhibitor Assembly?

The direct condensation of the free base derived from this hydrochloride with activated oxazolidinone intermediates is a key step in the synthesis of oral anticoagulants that contain a (3R)-aminopyrrolidine pharmacophore. In a documented kilogram-scale campaign, the hydrochloride was partitioned between 2-methyltetrahydrofuran and aqueous potassium carbonate (20 wt%) with vigorous agitation in a jacketed 500 L glass-lined reactor; the rate of base addition was calibrated to maintain the interfacial pH between 9.5 and 10.2, as pH excursions above 10.5 promote hydrolytic opening of the oxazolidinone ring of the electrophile. The organic phase, dried over molecular sieves 4A to a water content below 100 ppm (Karl Fischer titration per ASTM E203), is reacted with a chloroformate-activated oxazolidinone (0.98 eq) in the presence of 1-methylimidazole (0.1 eq) as an acylation catalyst. The coupling is performed at −15°C to −10°C for 6 h, conditions under which the competing pyrimidine ring chlorination is suppressed to less than 0.15 area% by HPLC at 254 nm. Enantiomeric purity is assayed at this point by derivatization with Marfey’s reagent (Nα-(2,4-dinitro-5-fluorophenyl)-L-alaninamide) followed by RP-HPLC using a USP L1 column and acetonitrile/0.1% phosphoric acid gradient; the ratio of diastereomers provides an ee determination with an expanded measurement uncertainty of ±0.2% (coverage factor k = 2). Typical production campaigns yield the protected penultimate intermediate in 81–84% yield after crystallization from isopropanol/water (2:1), with an ee of 99.7%. Residual solvent analysis follows USP 〈467〉 procedure A; isopropanol is controlled to ≤ 1000 ppm and 2-methyltetrahydrofuran to ≤ 500 ppm. This intermediate is telescoped into a multi-kilogram deprotection–sulfation sequence to yield the final Factor Xa inhibitor, which is micronized to a particle size distribution of d₉₀ ≤ 10 µm for direct compression tablet manufacture. The hydrochloride starting material is listed in the Type II drug master file and is subject to a supplier qualification audit verifying absence of nitrosamine impurities per the EMA/CMDh/418/2020 guideline, with quantitative determination by LC-MS/MS (method sensitivity: 0.03 ppm for N-nitrosodimethylamine).

When Continuous-Flow Amidations Demand Pre-Activated Carbamates

A process intensification route exploits the Boc-carbamate as a latent amine reservoir compatible with flow reactor amidation chemistry. The hydrochloride is dissolved in methanol and passed through a short column of immobilized carbonate resin (Amberlyst A-21, 1.5 eq by bed volume capacity) to generate the free base solution, which is concentrated under reduced pressure (40°C bath, 50 mbar) and redissolved in anhydrous THF. This stream is combined with a THF solution of an aryl acetic acid that has been pre-activated with isobutyl chloroformate and N-methylmorpholine at −20°C in a residence-time loop (PFA coil, 1.0 mm internal diameter, 10 mL volume). The two feeds are delivered by syringe pumps at a total flow rate of 0.5 mL/min through a micro-mixer chip (stainless steel, 0.25 mm channel width) and into a 15 mL coil reactor immersed in a 25°C bath, giving a precisely controlled residence time of 30 min. In-line FTIR (Mettler Toledo ReactIR 15 with DiComp probe) tracks the disappearance of the mixed-anhydride carbonyl stretch at 1825 cm⁻¹; when the absorbance falls below 5% of baseline, the exiting stream is quenched into aqueous citric acid (10 wt%) and extracted with ethyl acetate. Compared to batch amidation, the flow protocol reduces the formation of the homobenzylamide dimer impurity from 2.1% to 0.3% (HPLC area at 215 nm) and improves the throughput to 120 g/h of purified amide after silica plug filtration. The Boc group remains intact throughout the flow sequence and is subsequently cleaved with methanolic HCl (1.25M, 5 eq) under gentle reflux (50°C) for 3 h to deliver the secondary amine hydrochloride intermediate, which is poised for further N-sulfonylation in the preparation of selective glycine transporter 1 (GlyT1) inhibitors. Equipment clean-in-place validation between campaigns relies on total organic carbon (TOC) swab analysis following ASTM E2316-14, with acceptance criterion ≤ 5 µg/cm², to prevent cross-contamination.

Incorporation of a (3R)-pyrrolidine motif into peptide backbones restricts the phi and psi torsion angles in a manner analogous to a proline residue but with an additional hydrogen-bond-donating/accepting site, which is exploited to design metabolically stable peptidomimetics. The hydrochloride is first converted to the corresponding Fmoc-(3R)-aminopyrrolidine-1-carboxylate via a sequence of Boc removal and Fmoc protection. Boc deprotection is conducted with hydrogen chloride gas dissolved in anhydrous ethyl acetate at 0–5°C (4M, 10 eq of HCl); the precipitate of the dihydrochloride salt is collected by filtration under nitrogen, washed with cold ethyl acetate (−10°C), and immediately suspended in a mixture of dioxane and 10% aqueous sodium carbonate (2:1, 15 volumes). Emoc-OSu (1.05 eq) is added portionwise over 30 min while maintaining the temperature at 15°C, and the mixture is stirred until thin-layer chromatography (silica, chloroform/methanol/acetic acid 90:8:2) indicates complete consumption of the free amine. The resulting Fmoc-protected amino acid is incorporated into a solid-phase peptide synthesis (SPPS) sequence on a Rink amide MBHA resin (loading 0.6 mmol/g) using HCTU (4 eq) and 2,4,6-collidine (8 eq) in N-methyl-2-pyrrolidone as the coupling system. The pyrrolidine amine is coupled for 120 min with double coupling extending the total acylation time to 4 h; Kaiser test monitoring confirms completion. Following full-length assembly and TFA cleavage, the crude peptidomimetic containing the (3R)-aminopyrrolidine residue is purified by preparative reversed-phase HPLC (C18 column, acetonitrile/water with 0.1% TFA) and characterized by high-resolution mass spectrometry. Circular dichroism spectroscopy at 20°C in phosphate-buffered saline (pH 7.4) reveals a shift in the minimum molar ellipticity of −12,000 deg·cm²·dmol⁻¹ at 198 nm, confirming the induction of a polyproline II helix mimetic conformation essential for binding to the SH3 domain of the adaptor protein Grb2. The Fmoc intermediate derived from the title hydrochloride must meet an enantiomeric purity specification of ≥ 99.5% ee (chiral HPLC as above) and a chloride content below 0.5 wt% (argentometric titration) to avoid premature resin cleavage during acidic SPPS cycles.

Storage of 2-Methyl-2-propanyl (3R)-3-amino-1-pyrrolidinecarboxylate hydrochloride under ambient laboratory conditions for periods exceeding 72 h at relative humidity above 60% leads to surface hydration and partial hydrolysis of the carbamate, evidenced by a doublet at δ 3.45 ppm in the ¹H NMR spectrum corresponding to free pyrrolidine acetate. For campaigns requiring holding times longer than 48 h after container opening, the material is repackaged under argon in foil-laminate bags containing silica gel desiccant and stored at −20°C. The enthalpy of decomposition measured by differential scanning calorimetry (heating rate 10°C/min under nitrogen) exhibits an exotherm onset at 183°C with an energy release of −410 J/g; process safety evaluations therefore mandate avoidance of mechanical friction in milling operations and a maximum processing temperature of 60°C, enforced by independent interlock on all stirred-tank heating jackets. Combinations of this hydrochloride with strong oxidizing agents, notably sodium hypochlorite or concentrated nitric acid, must be strictly avoided because the tertiary pyrrolidine nitrogen undergoes rapid N-oxidation, forming a heterocyclic N-oxide that liberates the genotoxic hydroxylamine upon deprotection.